Follow BPI on Twitter
Full Text (PDF)
Everyone looks forward to the annual pharmaceutical company league tables from our colleagues at Scrip (also owned by Informa plc). The 2009 tables ranked companies according to their US dollar sales of prescription pharmaceuticals in 2008 to reveal a 12.5% rise in the number of “billionaire” companies. There was little change at the top of the biotech table, with Amgen and Genentech far ahead of all others in terms of product sales. Despite the economic downturn, many companies managed to turn in mostly robust sales performances. Only 11% of the top 100 saw their sales decline (www.scripnews.com).
Facility Design Strategies for Single-Use Technologies
Please join us for a free webinar addressing strategies for facility design in biopharmaceutical manufacturing:
Wednesday, 29 February 2012
8:00 AM and 1:00 PM EST
Presented by:
Ingrid Long, MSc
Research Engineer
GE Healthcare Life Sciences
During the webinar, Ms. Long will discuss the impact of different strategies for facility design, with a focus on the following topics:
* Replacement of traditional equipment with the single-use equivalent
* Biopharmaceutical manufacturing in a single room
* Benefits of facility design with respect to cost, risk, and flexibility
Development of a Plant-Made Pharmaceutical Production Platform
Recommendations for Cell Banks Used in GXP Assays
Efficient Aggregate Removal from Impure Pharmaceutical Active Antibodies
Implementation of Single-Use Technology in Biopharmaceutical Manufacturing
Production and Purification of a PER.C6-Expressed IgM Antibody Therapeutic
How QbD and the FDA Process Validation Guidance Affect Product Development and Operations, Part 2